Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. ABIVAX
  6. News
  7. Summary
    ABVX   FR0012333284

ABIVAX

(ABVX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Abivax : 2021 Universal Registration Document

04/29/2021 | 06:00pm EDT

depending on the top-line results of the dose escalation phase

UNIVERSAL REGISTRATION

DOCUMENT 2021

This Universal Registration Document was filed with the Autorité des marchés financiers, the French Financial Markets Authority, hereinafter the AMF, on 30 April 2021 as the competent authority under Regulation (EU) No 2017/1129, without prior approval in accordance with Article 9 of that Regulation.

The Universal Registration Document may be used for the purpose of offering financial securities to the public or for the admission of financial securities to trading in a regulated market if supplemented by a prospectus and, if applicable, a summary and all the amendments made to the Universal Registration Document. The resulting document package has been approved by the AMF in accordance with Regulation (EU) No 2017/1129.

Pursuant to Article 19 of Regulation (EU) No 2017/1129, the following information is included by reference in this Universal Registration Document:

  • For the 2019 financial year, the ABIVAX Registration Document filed with the AMF on 25 May 2020 under number D.20-0483, contains the historical parent company financial statements, the Statutory Auditor's reports, the Management report, as well as key figures about ABIVAX; and
  • For the 2018 financial year, the ABIVAX Registration Document filed with the AMF on 29 April 2019 under number D.19-
    0437, contains the historical parent company financial statements, the Statutory Auditor's reports, the Management report, as well as key figures about ABIVAX;

Copies of this Universal Registration Document are available free of charge from the Company at 5 rue de la Baume, 75008 Paris, France, as well as electronically on the Company's website (www.ABIVAX.com) and on the AMF's website (www.amf-france.org).

CONTENTS

GENERAL REMARKS..................................................................................................................................

5

1. PERSONS RESPONSIBLE, INFORMATION FROM A THIRD PARTY, EXPERTS' REPORT AND APPROVAL OF THE

COMPETENT AUTHORITY ...................................................................................................................................................

7

1.1

Person(s) responsible for the Universal Registration Document...............................................................

7

1.2

Statement by the Responsible Person ......................................................................................................

7

1.3

Name, address, qualifications and potential interests of persons involved as experts .............................

7

1.4

Statement about information from a third party......................................................................................

7

1.5

Declaration without prior approval by the competent authority..............................................................

7

2.

STATUTORY AUDITORS.............................................................................................................................................

8

2.1

Auditor.....................................................................................................................................................

8

2.2

Statutory auditors who have resigned or been dismissed ........................................................................

8

3.

RISK FACTORS ...........................................................................................................................................................

9

3.1

Risks related to the Company's business .................................................................................................

10

3.2

The Company's financial and market risks...............................................................................................

16

3.3

Regulatory and legal risks........................................................................................................................

20

3.4

Risks related to the Company's organisation...........................................................................................

24

4. INFORMATION ABOUT THE COMPANY..................................................................................................................

27

4.1

Legal and commercial name of the Company ..........................................................................................

27

4.2

Place, registration number and legal entity identifier of the Company....................................................

27

4.3

Date of incorporation and duration of the Company...............................................................................

27

4.4

Registered office, legal form, laws governing its operations....................................................................

27

5.

OVERVIEW OF ACTIVITIES ......................................................................................................................................

28

5.1

Main activities.........................................................................................................................................

28

5.2

Main markets ..........................................................................................................................................

51

5.3

Significant events in the growth of the Company's business since 2018 ..................................................

51

5.4

Strategy and objectives ...........................................................................................................................

53

5.5

Patents, licences, trademarks, names and domain names.......................................................................

54

5.6

The competitive environment .................................................................................................................

75

5.7

Investments ............................................................................................................................................

76

6.

ORGANISATIONAL STRUCTURE ..............................................................................................................................

77

6.1

Organisation of the Company..................................................................................................................

77

6.2

List of subsidiaries, branches and secondary establishments ..................................................................

77

7. REVIEW OF THE FINANCIAL POSITION AND OF THE RESULTS ...............................................................................

78

7.1

Financial position ....................................................................................................................................

78

7.2

Operating income....................................................................................................................................

86

8.

CASH AND CAPITAL.................................................................................................................................................

88

8.1

Information on the capital of the Company.............................................................................................

88

8.2

Sources and uses of cash of the Company ...............................................................................................

90

8.3

Financing needs and financing structure .................................................................................................

91

2 | UNIVERSAL REGISTRATION DOCUMENT 2021

8.4 Restrictions on the use of capital which have materially affected or may materially affect the Company's

operations directly or indirectly ............................................................................................................................

94

8.5

Expected sources of funding....................................................................................................................

94

9. REGULATORY ENVIRONMENT................................................................................................................................

97

9.1 Description of the regulatory environment and any measures of an administrative, economic, budgetary,

monetary and political nature...............................................................................................................................

97

10. INFORMATION ON TRENDS..................................................................................................................................

107

10.1

Main trends since the beginning of the current financial year ...............................................................

107

10.2 Trends, uncertainties, constraints, commitments or events likely to have a material impact on the

Company's outlook .............................................................................................................................................

107

11.

PROFIT FORECASTS OR ESTIMATES......................................................................................................................

109

12.

ADMINISTRATIVE, MANAGEMENT AND SUPERVISING BODIES AND GENERAL MANAGEMENT.......................

110

12.1

Executives, directors and non-voting directors......................................................................................

110

12.2

Conflicts of interest of administrative and executive bodies .................................................................

117

12.3 Procedure for the evaluation of agreements relating to current operations and concluded under normal

conditions ...........................................................................................................................................................

118

13. COMPENSATION AND BENEFITS ..........................................................................................................................

119

13.1

Executive compensation and benefits in kind........................................................................................

119

13.2 Sums provisioned by the Company for the payment of pensions, retirement benefits and other benefits

to corporate officers ...........................................................................................................................................

128

14. FUNCTIONING OF ADMINISTRATIVE AND MANAGEMENT BODIES ....................................................................

129

14.1

Expiry dates of terms of office...............................................................................................................

129

14.2

Information on the agreements between the executives and/or the directors and the Company.........

129

14.3

Information on the Audit Committee, the Compensation Committee and the Scientific Committee ....

129

14.4

Statement relating to corporate governance.........................................................................................

131

14.5

Potential significant impacts on corporate governance .........................................................................

132

14.6

Internal control of accounting and financial information ......................................................................

132

15.

EMPLOYEES...........................................................................................................................................................

133

15.1

Human resources ..................................................................................................................................

133

15.2

Shareholdings and stock options of corporate officers ..........................................................................

136

15.3

Agreement providing for shareholdings of employees ..........................................................................

136

16.

MAJOR SHAREHOLDERS .......................................................................................................................................

137

16.1

Breakdown of capital and voting rights .................................................................................................

137

16.2

Major shareholders' voting rights..........................................................................................................

139

16.3

Direct or indirect control of the Company .............................................................................................

139

16.4

Agreements that, when implemented, could result in a change of control............................................

140

16.5

Changes in share price...........................................................................................................................

140

17.

RELATED-PARTYTRANSACTIONS .........................................................................................................................

142

17.1

Details of related-party transactions .....................................................................................................

142

18. FINANCIAL INFORMATION ABOUT THE ISSUER'S ASSETS AND LIABILITIES, FINANCIAL POSITION AND RESULTS

145

18.1

Historical financial information .............................................................................................................

145

18.2

Interim and other financial information ................................................................................................

180

3 | UNIVERSAL REGISTRATION DOCUMENT 2021

18.3

Audit of historical annual financial information ....................................................................................

181

18.4

Pro forma financial information ............................................................................................................

181

18.5

Dividend policy......................................................................................................................................

181

18.6

Administrative, legal and arbitration proceedings.................................................................................

182

18.7

Significant changes in the financial or trading position..........................................................................

182

19.

ADDITIONAL INFORMATION ................................................................................................................................

183

19.1

Share capital..........................................................................................................................................

183

19.2

Charter and Articles of Association........................................................................................................

201

20.

MAJOR CONTRACTS..............................................................................................................................................

212

20.1

Collaboration and research and development contracts .......................................................................

212

20.2 Main contracts for the provision of services and mandates with clinical research organisations (CRO) and

centralised laboratories ......................................................................................................................................

212

20.3

Intellectual property rights assignment contract...................................................................................

213

20.4

Bpifrance aid contracts (grants and/or repayable advances) .................................................................

213

20.5

Other financial agreements ...................................................................................................................

217

21.

PUBLICLY AVAILABLE DOCUMENTS .....................................................................................................................

218

22.

MANAGEMENT REPORT CROSS-REFERENCETABLE ............................................................................................

219

22.1

Cross-reference table with the annual financial report..........................................................................

219

22.2

Cross-reference table with the management report..............................................................................

219

22.3

Cross-reference table with the report on corporate governance ...........................................................

220

4 | UNIVERSAL REGISTRATION DOCUMENT 2021

Disclaimer

Abivax SA published this content on 30 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 May 2021 13:39:03 UTC.


© Publicnow 2021
All news about ABIVAX
06/23GLOBAL MARKETS LIVE : Microsoft, Morgan Stanley, Heineken, Twitter, AstraZeneca...
06/23ABIVAX  : reports excellent phase 2a clinical safety and efficacy results with 5..
PU
06/23Abivax annonce d'excellents résultats -3-
DJ
06/23Abivax annonce d'excellents résultats -2-
DJ
06/23Abivax annonce d'excellents résultats d'efficacité et de tolérance avec 50 mg..
DJ
06/23PRESS RELEASE  : Abivax reports excellent phase 2a -2-
DJ
06/23PRESS RELEASE  : Abivax reports excellent phase 2a clinical safety and efficacy ..
DJ
06/23ABIVAX  : reports excellent phase 2a clinical safety and efficacy results with 5..
EQ
06/16ABIVAX  : Nombre d'actions composant le capital social et nombre total de droits..
DJ
06/07Abivax annonce les résultats de son Assemblée générale ordinaire annuelle et ..
DJ
More news
Financials
Sales 2021 99,4 M 119 M 119 M
Net income 2021 8,70 M 10,4 M 10,4 M
Net Debt 2021 37,4 M 44,6 M 44,6 M
P/E ratio 2021 -10,9x
Yield 2021 -
Capitalization 441 M 526 M 526 M
EV / Sales 2021 4,81x
EV / Sales 2022 694x
Nbr of Employees 27
Free-Float 55,7%
Chart ABIVAX
Duration : Period :
ABIVAX Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABIVAX
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 30,60 €
Average target price 58,63 €
Spread / Average Target 91,6%
EPS Revisions
Managers and Directors
NameTitle
Hartmut J. Ehrlich Chief Executive Officer
Didier Blondel Chief Financial Officer & Secretary
Philippe Pouletty Chairman
Didier Scherrer Vice President-Research & Development
Paul Gineste Vice President-Clinical Operations
Sector and Competitors
1st jan.Capitalization (M$)
ABIVAX-11.05%526
MODERNA, INC.102.97%85 140
LONZA GROUP AG13.57%52 316
IQVIA HOLDINGS INC.35.24%46 441
CELLTRION, INC.-22.42%33 893
SEAGEN INC.-10.43%28 470